Arctic Bioscience AS (DE:9TD) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Arctic Bioscience, a biotech firm focusing on bioactive marine compounds, is set to present results from the HeROPA clinical trial in a webcast on October 16, 2024, led by CEO Christer L. Valderhaug and Medical Director Runhild Gammelsæter. The company is actively developing a new drug, HRO350, aimed at treating mild-to-moderate psoriasis and markets nutraceuticals globally under the ROMEGA® brand.
For further insights into DE:9TD stock, check out TipRanks’ Stock Analysis page.
